Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02...
-
Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the...
-
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx...
-
WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules...
-
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
-
WATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing...
-
Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Recessive Dystrophic...
-
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for...
-
Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment of...
-
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced...